

EXHIBIT B


Filing Date: October 29, 2003

U.S. Application Serial No.: 10/697,720 Serial No.: 10/697,720
Title: Inflammation Tumor Susceptibility Genes and Their Uses Inventor(s): Stanley N. COHEN et al.

Attorney Docket No.: 700117.002/USC2

Receipt is hereby acknowledged for the following in the U.S. Patent and Trademark Office:

- Transmittal Form
- Response to Notice to Comply With Sequence Disclosure Requirements
- Substitute Sequence Listing - Paper Copy (11 Sheets)
- Substitute Sequence Listing - Computer Readable Form (1 Diskette)
- Statement Under 37 CFR 1.821-1.825 (1 page, executed)
- Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (return copy)
- Supplemental Preliminary Amendment
- Return Postcard



Patent


Due Date: June 11, 2006
SBK/DGK/pjc - DC Office

103

al

Sequence Disclosure Requirements

- Substitution Sequence Listing - Paper Copy (11 Sheets)
- Statement Under 37 CFR 1.821-1.825 (1 page, executed)
- Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (return copy)
- Supplemental Preliminary Amendment
- Return Postcard



Patent

Due Date: June 11, 2006
SBK/DGK/pjc - DC Office

TRANSMITTAL FORM

(to be used on all correspondence after initial filing)

ATTORNEY DOCKET NO.

70017.0027USC2

U.S. APPLICATION SERIAL NO.

10/697,720

CONFIRMATION NO.

3761

FILING DATE

October 29, 2003

INVENTOR(S)

Stanley N. COHEN et al.

EXAMINER

not yet assigned

GROUP ART UNIT

1642

TITLE OF APPLICATION

Mammalian Tumor Susceptibility Genes and Their Uses

ADDRESS TO:

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ENCLOSURES

- Transmittal Form
- Response to Notice to Comply With Sequence Disclosure Requirements
- Substitute Sequence Listing - Paper Copy (11 Sheets)
- Substitute Sequence Listing - Computer Readable Form (1 Diskette)
- Statement Under 37 CFR 1.821-1.825 (1 page, executed)
- Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (return copy)
- Supplemental Preliminary Amendment
- Return Postcard

Please charge Deposit Account No. 13-2725 in the amount of \$0.00 to cover any required fees. In the event any variance exists between this amount and the Patent Office charges for filing the above-noted documents, including any fees required under 35 CFR 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 13-2725. Further, if these papers are not considered timely filed, then a request is hereby made under 37 CFR 1.136 for the necessary extension of time.

CORRESPONDENCE ADDRESS

The address associated with Customer Number: **23552** OR the correspondence address below.


Name

Address

City

State

Zip Code

NAME	Steven B. Kelber	REGISTRATION NO.	30,073
SIGNATURE		DATE	May 9, 2006
NAME	Dawn Gardner Krosnick	REGISTRATION NO.	44,118

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE DISCLOSURE REQUIREMENTS		ATTORNEY DOCKET NO. 70017.0027USC2
INVENTOR(S) Stanley N. COHEN et al.	EXAMINER (if known) not yet assigned	U.S. APPLICATION SERIAL NO. 10/697,720 CONF. NO. 3761
TITLE OF APPLICATION Mammalian Tumor Susceptibility Genes and Their Uses		FILING DATE October 29, 2003
		ART UNIT (if known) 1642

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

Responsive to the notification dated April 11, 2006, and in accordance with the provisions of 37 C.F.R. 1.821-1.825, Applicants submit herewith a Substitute Sequence Listing (paper copy), a copy of the sequence listing in computer readable form on diskette, and a statement under 37 C.F.R. §1.821 - 1.825.

In view of the foregoing, this application is deemed to be in proper condition for examination on the merits and such favorable action is earnestly solicited.

Respectfully submitted,


MERCHANT & GOULD, P.C.



Steven B. Kelber
Registration No. 30,073

Dawn Gardner Krosnick
Registration No. 44,118

May 9, 2006
Date
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
Telephone No. (202) 326-0300
Facsimile No. (202) 326-0778



SEQUENCE LISTING

<110> Cohen, Stanley N.
Li, Limin

<120> MAMMALIAN TUMOR SUSCEPTIBILITY GENES AND THEIR USES

<130> 70017.27USC2

<140> US 10/697,720
<141> 2003-10-29

<150> US 09/804,690
<151> 2001-03-12

<150> US 09/146,187
<151> 1998-09-01

<150> US 08/977,818
<151> 1997-11-25

<150> US 08/670,274
<151> 1996-06-13

<150> US 08/585,758
<151> 1996-01-16

<150> US 60/006,856
<151> 1995-11-16

<160> 20

<170> PatentIn version 3.3

<210> 1
<211> 1448
<212> DNA
<213> Artificial Sequence

<220>
<223> TSG101 nucleotide

<220>
<221> CDS
<222> (61)..(1203)

<400> 1
ccacctctgcc tgtggggacg gaggagcgcg ccatggctgt ccgagagtca gctgaagaag 60
atg atg tcc aag tac aaa tat aga gat cta acc gtc cgt caa act gtc 108
Met Met Ser Lys Tyr Lys Tyr Arg Asp Leu Thr Val Arg Gln Thr Val
1 5 10 15
aat gtc atc gct atg tac aaa gat ctc aaa cct gta ttg gat tca tat 156
Asn Val Ile Ala Met Tyr Lys Asp Leu Lys Pro Val Leu Asp Ser Tyr
20 25 30
gtt ttt aat gat ggc agt tcc agg gag ctg gtg aac ctc act ggt aca 204
Val Phe Asn Asp Gly Ser Ser Arg Glu Leu Val Asn Leu Thr Gly Thr

35	40	45	
atc cca gtg cgt tat cga ggt aat ata tat aat att cca ata tgc ctg Ile Pro Val Arg Tyr Arg Gly Asn Ile Tyr Asn Ile Pro Ile Cys Leu	50	55	252
tgg ctg ctg gac aca tac cca tat aac ccc cct atc tgt ttt gtt aag Trp Leu Leu Asp Thr Tyr Pro Tyr Asn Pro Pro Ile Cys Phe Val Lys	65	70	300
cct act agt tca atg act att aaa aca gga aag cat gtg gat gca aat Pro Thr Ser Ser Met Thr Ile Lys Thr Gly Lys His Val Asp Ala Asn	85	90	348
ggg aaa atc tac cta cct tat cta cat gac tgg aaa cat cca cgg tca Gly Lys Ile Tyr Leu Pro Tyr Leu His Asp Trp Lys His Pro Arg Ser	100	105	396
gag ttg ctg gag ctt att caa atc atg att gtg ata ttt gga gag gag Glu Leu Leu Glu Leu Ile Gln Ile Met Ile Val Ile Phe Gly Glu Glu	115	120	444
cct cca gtg ttc tcc cgg cct act gtt tct gca tcc tac cca cca tac Pro Pro Val Phe Ser Arg Pro Thr Val Ser Ala Ser Tyr Pro Pro Tyr	130	135	492
aca gca aca ggg cca cca aat acc tcc tac atg cca ggc atg cca agt Thr Ala Thr Gly Pro Pro Asn Thr Ser Tyr Met Pro Gly Met Pro Ser	145	150	540
gga atc tct gca tat cca tct gga tac cct ccc aac ccc agt ggt tat Gly Ile Ser Ala Tyr Pro Ser Gly Tyr Pro Pro Asn Pro Ser Gly Tyr	165	170	588
cct ggc tgt cct tac cca cct gct ggc cca tac cct gcc aca aca agc Pro Gly Cys Pro Tyr Pro Pro Ala Gly Pro Tyr Pro Ala Thr Thr Ser	180	185	636
tca cag tac cct tcc cag cct gtc acc act gtt ggt ccc agc aga Ser Gln Tyr Pro Ser Gln Pro Pro Val Thr Thr Val Gly Pro Ser Arg	195	200	684
gat ggc aca atc agt gag gac act atc cgt gca tct ctc atc tca gca Asp Gly Thr Ile Ser Glu Asp Thr Ile Arg Ala Ser Leu Ile Ser Ala	210	215	732
gtc agt gac aaa ctg aga tgg cgg atg aag gag gaa atg gat ggt gcc Val Ser Asp Lys Leu Arg Trp Arg Met Lys Glu Glu Met Asp Gly Ala	225	230	780
cag gca gag ctt aat gcc ttg aaa cga aca gag gaa gat ctg aaa aaa Gln Ala Glu Leu Asn Ala Leu Lys Arg Thr Glu Glu Asp Leu Lys Lys	245	250	828
ggc cac cag aaa ctg gaa gag atg gtc acc cgc tta gat caa gaa gta Gly His Gln Lys Leu Glu Glu Met Val Thr Arg Leu Asp Gln Glu Val	260	265	876
gct gaa gtt gat aaa aac ata gaa ctt ttg aaa aag aag gat gaa gaa Ala Glu Val Asp Lys Asn Ile Glu Leu Leu Lys Lys Lys Asp Glu Glu			924

275	280	285	
ct a agt tct gct ctg gag aaa atg gaa aat caa tct gaa aat aat gat Leu Ser Ser Ala Leu Glu Lys Met Glu Asn Gln Ser Glu Asn Asn Asp	290	295	972
	300		
att gat gaa gtt atc att ccc aca gcc cca ctg tat aaa cag att cta Ile Asp Glu Val Ile Ile Pro Thr Ala Pro Leu Tyr Lys Gln Ile Leu	305	310	1020
	315		320
aat ctg tat gca gag gaa aat gct att gaa gac act atc ttt tac ctt Asn Leu Tyr Ala Glu Glu Asn Ala Ile Glu Asp Thr Ile Phe Tyr Leu	325	330	1068
	335		
gga gaa gct ttg cgg cgg gga gtc ata gac ctg gat gtg ttc ctg aaa Gly Glu Ala Leu Arg Arg Gly Val Ile Asp Leu Asp Val Phe Leu Lys	340	345	1116
	350		
cac gtc cgc ctc ctg tcc cgt aaa cag ttc cag cta agg gca cta atg His Val Arg Leu Leu Ser Arg Lys Gln Phe Gln Leu Arg Ala Leu Met	355	360	1164
	365		
caa aag gca agg aag act gcg ggc ctt agt gac ctc tac tgacatgtgc Gln Lys Ala Arg Lys Thr Ala Gly Leu Ser Asp Leu Tyr	370	375	1213
	380		
tgtcagctgg agaccgacct ctccgtaaag cattcttttc ttcttcttt tctcatcagt			1273
agaacccaca ataagttatt gcagtttatac attcaagtgt taaatattt gaatcaataa			1333
tatattttct gtttcctttg ggtaaaaact ggcttttatt aatgcacttt ctaccctctg			1393
taaggcgtctg tgcttgctg ggactgactg ggctaaataa aatttggcataataa ataaaa			1448

<210> 2
 <211> 381
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> TSG101 amino acid

<400> 2

Met Met Ser Lys Tyr Lys Tyr Arg Asp Leu Thr Val Arg Gln Thr Val
1 5 10 15

Asn Val Ile Ala Met Tyr Lys Asp Leu Lys Pro Val Leu Asp Ser Tyr
20 25 30

Val Phe Asn Asp Gly Ser Ser Arg Glu Leu Val Asn Leu Thr Gly Thr
35 40 45

Ile Pro Val Arg Tyr Arg Gly Asn Ile Tyr Asn Ile Pro Ile Cys Leu
50 55 60

Trp Leu Leu Asp Thr Tyr Pro Tyr Asn Pro Pro Ile Cys Phe Val Lys
65 70 75 80

Pro Thr Ser Ser Met Thr Ile Lys Thr Gly Lys His Val Asp Ala Asn
85 90 95

Gly Lys Ile Tyr Leu Pro Tyr Leu His Asp Trp Lys His Pro Arg Ser
100 105 110

Glu Leu Leu Glu Leu Ile Gln Ile Met Ile Val Ile Phe Gly Glu Glu
115 120 125

Pro Pro Val Phe Ser Arg Pro Thr Val Ser Ala Ser Tyr Pro Pro Tyr
130 135 140

Thr Ala Thr Gly Pro Pro Asn Thr Ser Tyr Met Pro Gly Met Pro Ser
145 150 155 160

Gly Ile Ser Ala Tyr Pro Ser Gly Tyr Pro Pro Asn Pro Ser Gly Tyr
165 170 175

Pro Gly Cys Pro Tyr Pro Pro Ala Gly Pro Tyr Pro Ala Thr Thr Ser
180 185 190

Ser Gln Tyr Pro Ser Gln Pro Pro Val Thr Thr Val Gly Pro Ser Arg
195 200 205

Asp Gly Thr Ile Ser Glu Asp Thr Ile Arg Ala Ser Leu Ile Ser Ala
210 215 220

Val Ser Asp Lys Leu Arg Trp Arg Met Lys Glu Glu Met Asp Gly Ala
225 230 235 240

Gln Ala Glu Leu Asn Ala Leu Lys Arg Thr Glu Glu Asp Leu Lys Lys
245 250 255

Gly His Gln Lys Leu Glu Glu Met Val Thr Arg Leu Asp Gln Glu Val
260 265 270

Ala Glu Val Asp Lys Asn Ile Glu Leu Leu Lys Lys Asp Glu Glu
275 280 285

Leu Ser Ser Ala Leu Glu Lys Met Glu Asn Gln Ser Glu Asn Asn Asp
290 295 300

Ile Asp Glu Val Ile Ile Pro Thr Ala Pro Leu Tyr Lys Gln Ile Leu
305 310 315 320

Asn Leu Tyr Ala Glu Glu Asn Ala Ile Glu Asp Thr Ile Phe Tyr Leu
325 330 335

Gly Glu Ala Leu Arg Arg Gly Val Ile Asp Leu Asp Val Phe Leu Lys
340 345 350

His Val Arg Leu Leu Ser Arg Lys Gln Phe Gln Leu Arg Ala Leu Met
355 360 365

Gln Lys Ala Arg Lys Thr Ala Gly Leu Ser Asp Leu Tyr
370 375 380

<210> 3
<211> 1494
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 3
gaagggtgtg cgattgtgtg ggacggctg gggcagccca gcagcggctg accctctgcc 60
tgcgggaaag ggagtcgcca ggcggccgtc atggcggtgt cggagagccca gctcaagaaa 120
atggtgtcca agtacaataa cagagaccta actgtacgtg aaactgtcaa tgttattact 180
ctatacaaag atctcaaacc tgaaaaatggat tcataatgttt ttaacgatgg cagttccagg 240
gaactaatga acctcactgg aacaatccct gtgccttata gaggtataac atacaatatt 300
ccaatatgcc tatggctact ggacacatac ccatataatc cccctatctg tttgttaag 360
cctactagtt caatgactat taaaacagga aagcatgttg atgcaaatgg gaagatataat 420
cttccttatac tacatgaatg gaaacaccca cagtcagact tggggct tattcaggtc 480
atgattgtgg tattttggaga tgaacctcca gtcttctctc gtcctatttc ggcattctat 540
ccggccataacc aggcaacggg gccacccaaat acttcctaca tgccaggcat gccaggtgga 600
atctctccat acccatccgg ataccctccc aatcccagtg gttaccagg ctgtccttac 660
ccacacctgg gtcctatcc tgccacaaca agttctcagt acccttctca gcctcctgtg 720
accactgttg gtcccaatgg ggtatggcaca atcagcgagg acaccatccg agcctctctc 780
atctctgcgg tcagtgacaa actgagatgg cggatgaagg aggaaatgg tcgtgcccag 840
gcagagctca atgccttgaa acgaacagaa gaagacctga aaaagggtca ccagaaactg 900

gaagagatgg ttacccgttt agatcaagaa gtagccgagg ttgataaaaa catagaactt	960
ttgaaaaaga aggatgaaga actcagttct gctctggaaa aaatggaaaa tcagtctgaa	1020
aacaatgata tcgatgaagt tatcattccc acagctccct tatacaaaca gatcctgaat	1080
ctgtatgcag aagaaaacgc tattgaagac actatcttt acttgggaga agccttgaga	1140
aggggcgtga tagacotgga tgtcttcctg aagcatgtac gtcttctgtc ccgtaaacag	1200
ttccagctga gggcactaat gcaaaaagca agaaagactg ccggctctcg tgacctctac	1260
tgacttctct gataccagct ggagggtttag ctcttcttaa agtattcttc tcttccttt	1320
atcagtaggt gcccagaata agttattgca gtttatcatt caagtgtaaa atatttgaa	1380
tcaataatat atttctgtt ttcttttgtt aaagactggc ttttattaaat gcactttcta	1440
tcctctgtaa acttttgtg ctgaatgttg ggactgctaa ataaaatttg tttt	1494

<210> 4
<211> 390
<212> PRT
<213> Artificial Sequence

<220>
<223> Primer

<400> 4

Met Ala Val Ser Glu Ser Gln Leu Lys Lys Met Val Ser Lys Tyr Lys			
1	5	10	15

Tyr Arg Asp Leu Thr Val Arg Glu Thr Val Asn Val Ile Thr Leu Tyr			
20	25	30	

Lys Asp Leu Lys Pro Val Leu Asp Ser Tyr Val Phe Asn Asp Gly Ser			
35	40	45	

Ser Arg Glu Leu Met Asn Leu Thr Gly Thr Ile Pro Val Pro Tyr Arg			
50	55	60	

Gly Asn Thr Tyr Asn Ile Pro Ile Cys Leu Trp Leu Leu Asp Thr Tyr			
65	70	75	80

Pro Tyr Asn Pro Pro Ile Cys Phe Val Lys Pro Thr Ser Ser Met Thr			
85	90	95	

Ile Lys Thr Gly Lys His Val Asp Ala Asn Gly Lys Ile Tyr Leu Pro			
100	105	110	

Tyr Leu His Glu Trp Lys His Pro Gln Ser Asp Leu Leu Gly Leu Ile

115

120

125

Gln Val Met Ile Val Val Phe Gly Asp Glu Pro Pro Val Phe Ser Arg
130 135 140

Pro Ile Ser Ala Ser Tyr Pro Pro Tyr Gln Ala Thr Gly Pro Pro Asn
145 150 155 160

Thr Ser Tyr Met Pro Gly Met Pro Gly Gly Ile Ser Pro Tyr Pro Ser
165 170 175

Gly Tyr Pro Pro Asn Pro Ser Gly Tyr Pro Gly Cys Pro Tyr Pro Pro
180 185 190

Gly Gly Pro Tyr Pro Ala Thr Thr Ser Ser Gln Tyr Pro Ser Gln Pro
195 200 205

Pro Val Thr Thr Val Gly Pro Ser Arg Asp Gly Thr Ile Ser Glu Asp
210 215 220

Thr Ile Arg Ala Ser Leu Ile Ser Ala Val Ser Asp Lys Leu Arg Trp
225 230 235 240

Arg Met Lys Glu Glu Met Asp Arg Ala Gln Ala Glu Leu Asn Ala Leu
245 250 255

Lys Arg Thr Glu Glu Asp Leu Lys Lys Gly His Gln Lys Leu Glu Glu
260 265 270

Met Val Thr Arg Leu Asp Gln Glu Val Ala Glu Val Asp Lys Asn Ile
275 280 285

Glu Leu Leu Lys Lys Lys Asp Glu Glu Leu Ser Ser Ala Leu Glu Lys
290 295 300

Met Glu Asn Gln Ser Glu Asn Asn Asp Ile Asp Glu Val Ile Ile Pro
305 310 315 320

Thr Ala Pro Leu Tyr Lys Gln Ile Leu Asn Leu Tyr Ala Glu Glu Asn
325 330 335

Ala Ile Glu Asp Thr Ile Phe Tyr Leu Gly Glu Ala Leu Arg Arg Gly
340 345 350

Val Ile Asp Leu Asp Val Phe Leu Lys His Val Arg Leu Leu Ser Arg

<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 9
ctgataccag ctggagggtt agctttc

28

<210> 10
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 10
atttagcagt cccaacatcc agcacaaa

28

<210> 11
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 11
gagaccgacc tctccgtaaa gcatttt

28

<210> 12
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 12
tagccccagtc agtcccagca cagcacag

28

<210> 13
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 13
atttagcagt cccaacatcc agcacaaa

28

<210> 14

<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 14
gtcttctggg tggcagtat ggcat 25

<210> 15
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 15
cggtgtcgg agagccagct caagaaa 27

<210> 16
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 16
ccttacccac ctgggtgtcc atatcctg 28

<210> 17
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 17
cctccagctg gtatcagaga agtcgt 26

<210> 18
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 18
cacagtcaga cttgttgggg cttattc 27

<210> 19

<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Primer

<400> 19

His Thr His Leu Ala Met Asx Asp Ala
1 5

<210> 20
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Primer

<220>
<221> VARIANT
<222> (2)...(2)
<223> Xaa is any amino acid

<400> 20

Phe Xaa Asn Gly Ala Leu Glx Cys Tyr Ser
1 5 10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

STATEMENT UNDER 37 C.F.R. § 1.821-1.825		ATTORNEY DOCKET NO. 70017.0027USC2
		U.S. APPLICATION SERIAL NO. 10/697,720
		CONFIRMATION NO. 3761
		FILING DATE October 29, 2003
INVENTOR(S) Stanley N. COHEN et al.	EXAMINER (If known) not yet assigned	ART UNIT (If known) 1642
TITLE OF APPLICATION Mammalian Tumor Susceptibility Genes and Their Uses		

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Dawn Gardner Krosnick, declare as follows:

1. That, in accordance with 37 C.F.R. § 1.821(f), the contents of the paper copy of the substitute sequence listing submitted herewith is a true copy of the sequence listing recorded in computer readable form which is also submitted herewith; and
2. That, in accordance with 37 C.F.R. § 1.821(g), the submission filed herewith does not include new matter.

Respectfully submitted,

MERCHANT & GOULD, P.C.




Steven B. Kelber
Registration No. 30,073

Dawn Gardner Krosnick
Registration No. 44,118

May 9, 2006

Date
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
Telephone No. (202) 326-0300
Facsimile No. (202) 326-0778





UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/697,720	10/29/2003	Stanley N. Cohen	5398-027-27 CONT

CONFIRMATION NO. 3761

23552
 MERCHANT & GOULD PC
 P.O. BOX 2903
 MINNEAPOLIS, MN 55402-0903

FORMALITIES
LETTER

Date Mailed: 04/11/2006

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>
 For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450
 Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in black ink, appearing to read "Murphy".

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART 2 - COPY TO BE RETURNED WITH RESPONSE



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 101697720
Source: TFW0
Date Processed by STIC: 7/6/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT
MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER**

VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - cPAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04



IFWO

RAW SEQUENCE LISTING DATE: 07/06/2004
 PATENT APPLICATION: US/10/697,720 TIME: 11:03:58

Input Set : A:\5398-027-27CONT.ST25.txt
 Output Set: N:\CRF4\07062004\J697720.raw

3 <110> APPLICANT: Cohen, Stanley N.
 4 Li, Limin
 6 <120> TITLE OF INVENTION: Mammalian Tumor Susceptibility Genes and Their Uses
 8 <130> FILE REFERENCE: 5398-027-27CONT
 10 <140> CURRENT APPLICATION NUMBER: US 10/697,720
 11 <141> CURRENT FILING DATE: 2003-10-29
 13 <150> PRIOR APPLICATION NUMBER: US 09/804,690
 14 <151> PRIOR FILING DATE: 2001-03-12
 16 <150> PRIOR APPLICATION NUMBER: US 09/146,187
 17 <151> PRIOR FILING DATE: 1998-09-01
 19 <150> PRIOR APPLICATION NUMBER: US 08/977,818
 20 <151> PRIOR FILING DATE: 1997-11-25
 22 <150> PRIOR APPLICATION NUMBER: US 08/670,274
 23 <151> PRIOR FILING DATE: 1996-06-13
 25 <150> PRIOR APPLICATION NUMBER: US 08/585,758
 26 <151> PRIOR FILING DATE: 1996-01-16
 28 <150> PRIOR APPLICATION NUMBER: US 60/006,856
 29 <151> PRIOR FILING DATE: 1995-11-16
 31 <160> NUMBER OF SEQ ID NOS: 20
 33 <170> SOFTWARE: FastSEQ for Windows Version 4.0

Does Not Comply
 Corrected Diskette Needed

(pg. 1-2)

ERRORED SEQUENCES

326 <210> SEQ ID NO: 7
 327 <211> LENGTH: 39
 328 <212> TYPE: RNA
 329 <213> ORGANISM: Artificial Sequence
 331 <220> FEATURE:
 332 <223> OTHER INFORMATION: primer
 334 <400> SEQUENCE: 7
 E--> 335 caucaucauc augaggaggc tttttttttt tttttccag
 337 <210> SEQ ID NO: 8
 338 <211> LENGTH: 39
 339 <212> TYPE: RNA
 340 <213> ORGANISM: Artificial Sequence
 342 <220> FEATURE:
 343 <223> OTHER INFORMATION: primer
 345 <400> SEQUENCE: 8
 E--> 346 cuacuacuac uacaccc ttttt gagcaagtcc agccggttt

No "t's" are allowed
 in a RNA sequence.

39
 Same error

VERIFICATION SUMMARY
PATENT APPLICATION: US/10/697,720

DATE: 07/06/2004
TIME: 11:03:59

Input Set : A:\5398-027-27CONT.ST25.txt
Output Set: N:\CRF4\07062004\J697720.raw

L:43 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order!
L:46 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:1
L:335 M:321 E: (1) "t" not allowed in RNA Sequence, NUMBER OF INVALID 't' KEYS:10 ✓
L:346 M:321 E: (1) "t" not allowed in RNA Sequence, NUMBER OF INVALID 't' KEYS:9
L:479 M:281 W: Numeric Fields not Ordered, <221> Sort in ascending order!
L:483 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:20
L:484 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20 after pos.:0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SUPPLEMENTAL PRELIMINARY AMENDMENT		ATTORNEY DOCKET NO. 70017.0027USC2
		U.S. APPLICATION SERIAL NO. 10/697,720
		CONFIRMATION NO. 3761
		FILING DATE October 29, 2003
INVENTOR(S) Stanley N. COHEN et al.	EXAMINER not yet assigned	GROUP ART UNIT 1642
TITLE OF APPLICATION Mammalian Tumor Susceptibility Genes and Their Uses		

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Supplementing the Preliminary Amendment filed October 29, 2003, and the Response to Notice to Comply and Preliminary Amendment filed on June 29, 2004, and prior to examination on the merits, please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

A current listing of the Claims begins on page 3 of this paper.

Remarks begin on page 4 of this paper.

Amendments to the Specification:

After page 46, between the specification and claims, please insert the paper copy of the Substitute Sequence Listing filed herewith, replacing the Sequence Listing previously submitted on June 29, 2004.

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1 - 23. (Canceled)

24. (Previously Presented) A substantially purified polypeptide comprising the full length human TSG101 protein encoded by a 1494 bp cloned human cDNA insert (SEQ ID NO:3).

25. (Previously Presented) The purified polypeptide of claim 24, wherein said 1494 bp cloned human cDNA insert (SEQ ID NO:3) is deposited as ATCC Accession No. PTA-5265 in cloning vector pAMP1.

26. (Previously Presented) A substantially purified polypeptide comprising the human TSG101 protein as described by the amino acid sequence of GenBank Accession No. U82130.

27. (Previously Presented) A substantially purified polypeptide comprising the amino acid sequence of SEQ ID NO:4.

28. (Previously Presented) A composition comprising a substantially purified polypeptide of any one of claims 24-27 in conjunction with a suitable pharmaceutical carrier.

REMARKS

Claims 24-28 are currently pending in this application.

The specification has been amended by adding the Substitute Sequence Listing filed herewith which replaces the Substitute Sequence Listing filed June 29, 2004 containing errored sequences.

No new matter has been added.

CONCLUSION

Applicants respectfully submit that the present application is in condition for examination on the merits. If the Examiner believes a telephone conference would advance the prosecution of this application, the Examiner is invited to telephone the undersigned at the below-listed telephone number.

Respectfully submitted,

MERCHANT & GOULD P.C.



Steven B. Kelber
Registration No. 30,073

May 9, 2006

Date

P.O. Box 2903
Minneapolis, Minnesota 55402-0903
Telephone No. (202) 326-0300
Facsimile No. (202) 326-0778

Dawn Gardner Krosnick
Registration No. 44,118

